<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04511624</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI112A101</org_study_id>
    <nct_id>NCT04511624</nct_id>
  </id_info>
  <brief_title>Single Dose Tolerability and Pharmacokinetic of IBI112 in Healthy Subjects</brief_title>
  <official_title>A Phase I Randomized, Double-Blind, Placebo-Controlled, Single Subcutaneous or Intravenous Ascending Dose Trial to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IBI112 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a the first in human study to evaluate the safety, tolerability, PK and PD of single&#xD;
      subcutaneous or intravenous dose of IBI112 in healthy subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this first in human, phase 1, randomized, double-blind, placebo-controlled study, a single&#xD;
      subcutaneous or intravenous dose of IBI112 will be administered to 46 healthy subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 27, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events in healthy volunteers with single ascending doses of IBI112</measure>
    <time_frame>Day1 to Day 113 post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) - Pharmacokinetic Assessment</measure>
    <time_frame>Day 113</time_frame>
    <description>IV dose &amp; SC dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Concentration (Tmax) - Pharmacokinetic Assessment</measure>
    <time_frame>Day 113</time_frame>
    <description>SC dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve Extrapolated to Infinity (AUC0-âˆž) - Pharmacokinetic Assessment</measure>
    <time_frame>Day 113</time_frame>
    <description>IV dose &amp; SC dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-Life (t1/2) - Pharmacokinetic Assessment</measure>
    <time_frame>Day 113</time_frame>
    <description>IV dose &amp; SC dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (Vd) - Pharmacokinetic Assessment</measure>
    <time_frame>Day 113</time_frame>
    <description>IV dose &amp; SC dose</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBI112 SC dose1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBI112 SC dose2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBI112 SC dose3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBI112 IV dose4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBI112 IV dose3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBI112 SC dose5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBI112 IV dose5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI112 dose1</intervention_name>
    <description>Drug: IBI112 SC dose1 Drug:placebo</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI112 dose2</intervention_name>
    <description>Drug: IBI112 SC dose2 Drug:placebo</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI112 dose3</intervention_name>
    <description>Drug: IBI112 SC dose3 Drug:placebo</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI112 dose4</intervention_name>
    <description>Drug: IBI112 SC dose4 Drug:placebo</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI112 dose5</intervention_name>
    <description>Drug: IBI112 IV dose5 Drug:placebo</description>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI112 dose6</intervention_name>
    <description>Drug: IBI112 SC dose6 Drug:placebo</description>
    <arm_group_label>Cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI112 dose7</intervention_name>
    <description>Drug: IBI112 IV dose7 Drug:placebo</description>
    <arm_group_label>Cohort 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or female 18 to 45 years of age at the time of consent&#xD;
&#xD;
          2. BMI of 19-26Kg/m2 and weight of 50-100kg&#xD;
&#xD;
          3. Must provide written informed consent, and in the investigator's opinion, subject is&#xD;
             able to understand the nature of the study and any risks involved in participation,&#xD;
             and willing to cooperate and comply with the protocol restrictions and requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have a medical history of liver, kidney, cardiovascular, nervous /&#xD;
             mental, gastrointestinal, respiratory, urinary, endocrine&#xD;
&#xD;
          2. Subjects who have a history of relapse or chronic infection, or a history of acute&#xD;
             infection within 2 weeks;&#xD;
&#xD;
          3. Subjects who have previously used anti-IL-12 / 23 or anti-il-23 drugs;&#xD;
&#xD;
          4. Subjects who have clinically significant abnormalities determined by vital signs,&#xD;
             physical examination, and laboratory measurements;&#xD;
&#xD;
          5. Subjects who are not suitable for this trial due to other reasons In the investigator'&#xD;
             opinion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Huashan Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

